Wird geladen...

Response to post-axitinib treatment in patients with metastatic renal cell carcinoma

BACKGROUND: Axitinib is a potent inhibitor of the vascular endothelial growth factor (VEGF) receptor family with clinical activity in patients with metastatic renal cell carcinoma (mRCC). Given this biochemical potency, the clinical activity of subsequent treatment with targeted therapies in patient...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC Cancer
Hauptverfasser: Chittoria, Namita, Haddad, Housam, Elson, Paul, Tannir, Nizar M., Wood, Laura S., Dreicer, Robert, Garcia, Jorge A., Rini, Brian I., Jonasch, Eric
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2016
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4810513/
https://ncbi.nlm.nih.gov/pubmed/27026229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2282-5
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!